Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Intangibles (2016 - 2026)

Myriad Genetics has reported Intangibles over the past 16 years, most recently at $153.4 million for Q4 2025.

  • Quarterly Intangibles fell 41.54% to $153.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.4 million through Dec 2025, down 41.54% year-over-year, with the annual reading at $153.4 million for FY2025, 41.54% down from the prior year.
  • Intangibles was $153.4 million for Q4 2025 at Myriad Genetics, down from $163.1 million in the prior quarter.
  • Over five years, Intangibles peaked at $559.9 million in Q1 2021 and troughed at $153.4 million in Q4 2025.
  • The 5-year median for Intangibles is $357.7 million (2023), against an average of $337.3 million.
  • Year-over-year, Intangibles fell 3.83% in 2023 and then plummeted 47.81% in 2025.
  • A 5-year view of Intangibles shows it stood at $404.1 million in 2021, then fell by 6.04% to $379.7 million in 2022, then decreased by 7.95% to $349.5 million in 2023, then fell by 24.92% to $262.4 million in 2024, then crashed by 41.54% to $153.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Intangibles are $153.4 million (Q4 2025), $163.1 million (Q3 2025), and $170.1 million (Q2 2025).